Last reviewed · How we verify

Intermittent preventive treatment:sulphadoxine-pyrimethamine

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

Intermittent preventive treatment:sulphadoxine-pyrimethamine is a Antifolate antimalarial combination Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Intermittent preventive treatment of malaria in pregnant women, Intermittent preventive treatment of malaria in infants.

Sulphadoxine-pyrimethamine is a fixed-dose antimalarial combination that inhibits folate synthesis in Plasmodium parasites, preventing malaria infection when given intermittently as preventive treatment.

Sulphadoxine-pyrimethamine is a fixed-dose antimalarial combination that inhibits folate synthesis in Plasmodium parasites, preventing malaria infection when given intermittently as preventive treatment. Used for Intermittent preventive treatment of malaria in pregnant women, Intermittent preventive treatment of malaria in infants.

At a glance

Generic nameIntermittent preventive treatment:sulphadoxine-pyrimethamine
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntifolate antimalarial combination
TargetDihydropteroate synthase and dihydrofolate reductase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Sulphadoxine and pyrimethamine are antifolate agents that sequentially block dihydropteroate synthase and dihydrofolate reductase in the parasite's folate metabolism pathway. This dual inhibition prevents DNA synthesis and replication in Plasmodium species. Intermittent preventive treatment (IPT) involves periodic dosing to maintain protective drug levels and prevent malaria parasitemia in at-risk populations, particularly pregnant women and infants in endemic areas.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intermittent preventive treatment:sulphadoxine-pyrimethamine

What is Intermittent preventive treatment:sulphadoxine-pyrimethamine?

Intermittent preventive treatment:sulphadoxine-pyrimethamine is a Antifolate antimalarial combination drug developed by London School of Hygiene and Tropical Medicine, indicated for Intermittent preventive treatment of malaria in pregnant women, Intermittent preventive treatment of malaria in infants.

How does Intermittent preventive treatment:sulphadoxine-pyrimethamine work?

Sulphadoxine-pyrimethamine is a fixed-dose antimalarial combination that inhibits folate synthesis in Plasmodium parasites, preventing malaria infection when given intermittently as preventive treatment.

What is Intermittent preventive treatment:sulphadoxine-pyrimethamine used for?

Intermittent preventive treatment:sulphadoxine-pyrimethamine is indicated for Intermittent preventive treatment of malaria in pregnant women, Intermittent preventive treatment of malaria in infants.

Who makes Intermittent preventive treatment:sulphadoxine-pyrimethamine?

Intermittent preventive treatment:sulphadoxine-pyrimethamine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is Intermittent preventive treatment:sulphadoxine-pyrimethamine in?

Intermittent preventive treatment:sulphadoxine-pyrimethamine belongs to the Antifolate antimalarial combination class. See all Antifolate antimalarial combination drugs at /class/antifolate-antimalarial-combination.

What development phase is Intermittent preventive treatment:sulphadoxine-pyrimethamine in?

Intermittent preventive treatment:sulphadoxine-pyrimethamine is in Phase 3.

What are the side effects of Intermittent preventive treatment:sulphadoxine-pyrimethamine?

Common side effects of Intermittent preventive treatment:sulphadoxine-pyrimethamine include Gastrointestinal disturbances, Rash, Folate deficiency, Allergic reactions.

What does Intermittent preventive treatment:sulphadoxine-pyrimethamine target?

Intermittent preventive treatment:sulphadoxine-pyrimethamine targets Dihydropteroate synthase and dihydrofolate reductase and is a Antifolate antimalarial combination.

Related